MBX

SEC source: 0001193125-26-335373 · ownership.xml · nonDerivative · entry 1

Azoulay Salomon · CIK 0002030246 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 14,399

F1 · shares: The sales reported on this Form 4 represent shares of common stock sold by the Reporting Person to cover tax obligations in connection with the vesting of restricted stock units, pursuant to a mandatory sell-to-cover agreement between the Reporting Person and the Company.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold on an aggregate basis for all Company participants, at prices ranging from $65.21 to $66.43, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the aggregate number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001193125-26-331642 · ownership.xml · derivative · entry 2

Smither John W · CIK 0001559583 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 130,000

Underlying: Common Stock · 130,000 shares

Expires 2036-08-03

F2 · derivative.exercise_date: The options will vest and become exercisable with 25% of the shares subject to the award vesting on July 13, 2027 and the remainder vesting in 36 equal monthly installments thereafter, subject to continued service on each such vesting date.

SEC source: 0001193125-26-331642 · ownership.xml · nonDerivative · entry 1

Smither John W · CIK 0001559583 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 28,000

F1 · shares: Represents the grant of restricted stock units ("RSUs"). 25% of the shares subject to the RSU grant will vest annually over four years, on each July 13, 2027, 2028, 2029 and 2030, subject to continued service on each such vesting date.

SEC source: 0001193125-26-331639 · ownership.xml · derivative · entry 3

Hoerter Steven L. · CIK 0001533451 · Director · President and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 331,000

Underlying: Common Stock · 331,000 shares

Expires 2036-08-03

F3 · derivative.exercise_date: The options will vest and become exercisable with 25% of the shares subject to the award vesting on July 13, 2027 and the remainder vesting in 36 equal monthly installments thereafter, subject to continued service on each such vesting date.

SEC source: 0001193125-26-331639 · ownership.xml · nonDerivative · entry 1

Hoerter Steven L. · CIK 0001533451 · Director · President and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 82,938

F1 · shares: Represents the grant of restricted stock units ("RSUs"). 25% of the shares subject to the RSU grant will vest annually over four years, on each July 13, 2027, 2028, 2029 and 2030, subject to continued service on each such vesting date.

SEC source: 0001193125-26-259236 · ownership.xml · derivative · entry 1

Mathers Edward T · CIK 0001328625 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 12,500

Underlying: Common Stock · 12,500 shares

Expires 2036-06-04

F1 · derivative.exercise_date: The grant will vest in full on the earlier of the one-year anniversary of the grant date or on the date of our next annual meeting of stockholders, subject to the non-employee director's continued services to the Company.

SEC source: 0001193125-26-258436 · ownership.xml · derivative · entry 2

Pescovitz Ora H. · CIK 0001519624 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 12,500

Underlying: Common Stock · 12,500 shares

Expires 2036-06-04

F1 · derivative.exercise_date: The grant will vest in full on the earlier of the one-year anniversary of the grant date or on the date of our next annual meeting of stockholders, subject to the non-employee director's continued services to the Company.

SEC source: 0001193125-26-258435 · ownership.xml · derivative · entry 1

Heron Patrick J · CIK 0001365617 · Director · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 12,500

Underlying: Common Stock · 12,500 shares

Expires 2036-06-04

F1 · derivative.exercise_date: The grant will vest in full on the earlier of the one-year anniversary of the grant date or on the date of our next annual meeting of stockholders, subject to the non-employee director's continued services to the Company.

SEC source: 0001193125-26-258432 · ownership.xml · derivative · entry 1

Stelzer Laurie · CIK 0001644348 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 12,500

Underlying: Common Stock · 12,500 shares

Expires 2036-06-04

F1 · derivative.exercise_date: The grant will vest in full on the earlier of the one-year anniversary of the grant date or on the date of our next annual meeting of stockholders, subject to the non-employee director's continued services to the Company.

SEC source: 0001193125-26-258429 · ownership.xml · derivative · entry 3

Hoerter Steven L. · CIK 0001533451 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 12,500

Underlying: Common Stock · 12,500 shares

Expires 2036-06-04

F2 · derivative.exercise_date: The grant will vest in full on the earlier of the one-year anniversary of the grant date or on the date of our next annual meeting of stockholders, subject to the non-employee director's continued services to the Company.

SEC source: 0001193125-26-258422 · ownership.xml · derivative · entry 1

Ryder Steven · CIK 0001872868 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 12,500

Underlying: Common Stock · 12,500 shares

Expires 2036-06-04

F1 · derivative.exercise_date: The grant will vest in full on the earlier of the one-year anniversary of the grant date or on the date of our next annual meeting of stockholders, subject to the non-employee director's continued services to the Company.

SEC source: 0001193125-26-258420 · ownership.xml · derivative · entry 1

Aynechi Tiba · CIK 0001669220 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 12,500

Underlying: Common Stock · 12,500 shares

Expires 2036-06-04

F1 · derivative.exercise_date: The grant will vest in full on the earlier of the one-year anniversary of the grant date or on the date of our next annual meeting of stockholders, subject to the non-employee director's continued services to the Company.

SEC source: 0001193125-26-216704 · ownership.xml · derivative · entry 6

Azoulay Salomon · CIK 0002030246 · Chief Medical Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 30,008

Underlying: Common Stock · 15,003 shares

Expires 2034-09-12

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F5 · derivative.exercise_date: 25% of the shares underlying this option vested and became exercisable on September 12, 2025, with the remaining 75% vesting in thirty-six (36) substantially equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date.

SEC source: 0001193125-26-216704 · ownership.xml · derivative · entry 5

Azoulay Salomon · CIK 0002030246 · Chief Medical Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 194,540

Underlying: Common Stock · 55,000 shares

Expires 2034-08-02

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_date: 25% of the shares underlying this option vested and became exercisable on June 24, 2025, with the remaining 75% vesting in thirty-six (36) substantially equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date.

SEC source: 0001193125-26-216704 · ownership.xml · nonDerivative · entry 4

Azoulay Salomon · CIK 0002030246 · Chief Medical Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 14,769

F1 · date: The sales reported on this Form 4 represent the exercise and sale of common stock options by the reporting person pursuant to an approved Rule 10b5-1 trading plan adopted on January 27, 2026.

F3 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $35.00 to $41.26, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

SEC source: 0001193125-26-216704 · ownership.xml · nonDerivative · entry 3

Azoulay Salomon · CIK 0002030246 · Chief Medical Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 29,772

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · date: The sales reported on this Form 4 represent the exercise and sale of common stock options by the reporting person pursuant to an approved Rule 10b5-1 trading plan adopted on January 27, 2026.

SEC source: 0001193125-26-216704 · ownership.xml · nonDerivative · entry 2

Azoulay Salomon · CIK 0002030246 · Chief Medical Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 14,769

F1 · date: The sales reported on this Form 4 represent the exercise and sale of common stock options by the reporting person pursuant to an approved Rule 10b5-1 trading plan adopted on January 27, 2026.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $35.00 to $41.26, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

SEC source: 0001193125-26-216704 · ownership.xml · nonDerivative · entry 1

Azoulay Salomon · CIK 0002030246 · Chief Medical Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 69,769

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · date: The sales reported on this Form 4 represent the exercise and sale of common stock options by the reporting person pursuant to an approved Rule 10b5-1 trading plan adopted on January 27, 2026.

SEC source: 0001193125-26-214574 · ownership.xml · nonDerivative · entry 1

Hawryluk P. Kent · CIK 0001673991 · Director · President & CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 727,667

F1 · kind: The sales reported on this Form 4 represent shares of common stock sold by the Reporting Person to cover tax obligations in connection with the vesting of restricted stock units, pursuant to a mandatory sell-to-cover agreement between the Reporting Person and the Company.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold on an aggregrate basis for all Company participants, at prices ranging from $29.23 to $29.88, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the aggregrate number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001193125-26-214582 · ownership.xml · nonDerivative · entry 1

Azoulay Salomon · CIK 0002030246 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 14,769

F1 · shares: The sales reported on this Form 4 represent shares of common stock sold by the Reporting Person to cover tax obligations in connection with the vesting of restricted stock units, pursuant to a mandatory sell-to-cover agreement between the Reporting Person and the Company.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold on an aggregate basis for all Company participants, at prices ranging from $29.23 to $29.88, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the aggregate number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001193125-26-202615 · ownership.xml · derivative · entry 3

Hoerter Steven L. · CIK 0001533451 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 74,249

Underlying: Common Stock · 74,249 shares

Expires 2036-05-01

F3 · derivative.exercise_date: The grant will vest 50% upon grant date and the remaining 50% in equal monthly installments over a six-month period from the grant date, subject to the Reporting Person's continued services to the Company.

SEC source: 0001193125-26-202615 · ownership.xml · nonDerivative · entry 1

Hoerter Steven L. · CIK 0001533451 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 11,938

F1 · shares: Represents the grant of restricted stock units (RSUs). The RSUs will vest in full on November 6, 2026, subject to the Reporting Person's continued service on such vesting date.

SEC source: 0001193125-26-107268 · ownership.xml · nonDerivative · entry 2

Hawryluk P. Kent · CIK 0001673991 · Director · President & CEO

10b5-1 filing: No plan indicated

Ownership: Indirect · By Trust

Disclosed balance after: 486,777

F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $28.28 to $28.48, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

F2 · ownership.nature: Shares held by the P. Kent Hawryluk Revocable Trust dated January 25, 2011, of which the Reporting Person serves as trustee. The Reporting Person disclaims beneficial ownership except to the extent of any pecuniary interest therein, and this report shall not be deemed an admission that such shares are beneficially owned by him for Section 16 or any other purpose.

SEC source: 0001193125-26-082562 · ownership.xml · derivative · entry 3

Hawryluk P. Kent · CIK 0001673991 · Director · President & CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 91,668

Underlying: Common Stock · 28,768 shares

Expires 2034-09-12

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_date: 25% of the shares underlying this option vested and became exercisable on September 12, 2025, with the remaining 75% vesting in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date.

SEC source: 0001193125-26-082562 · ownership.xml · nonDerivative · entry 1

Hawryluk P. Kent · CIK 0001673991 · Director · President & CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 728,274

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001193125-26-035582 · ownership.xml · derivative · entry 3

Hawryluk P. Kent · CIK 0001673991 · Director · President & CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 164,500

Underlying: Common Stock · 164,500 shares

Expires 2036-02-02

F3 · derivative.exercise_date: The shares underlying this option vest and become exercisable in forty eight (48) equal monthly installments, beginning on March 2, 2026, subject to the Reporting Person's continued service on such vesting date.

SEC source: 0001193125-26-035582 · ownership.xml · nonDerivative · entry 1

Hawryluk P. Kent · CIK 0001673991 · Director · President & CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 699,506

F1 · shares: Represents the grant of restricted stock units (RSUs). The RSUs will vest over a four (4) year period in equal quarterly installments, subject to the Reporting Person's continued service on such vesting date.

SEC source: 0001193125-26-035587 · ownership.xml · derivative · entry 2

Azoulay Salomon · CIK 0002030246 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 70,000

Underlying: Common Stock · 70,000 shares

Expires 2036-02-02

F2 · derivative.exercise_date: The shares underlying this option vest and become exercisable in forty eight (48) equal monthly installments, beginning on March 2, 2026, subject to the Reporting Person's continued service on such vesting date.

SEC source: 0001193125-26-035587 · ownership.xml · nonDerivative · entry 1

Azoulay Salomon · CIK 0002030246 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 15,000

F1 · shares: Represents the grant of restricted stock units (RSUs). The RSUs will vest over a four (4) year period in equal quarterly installments, subject to the Reporting Person's continued service on such vesting date.

SEC source: 0001193125-26-035584 · ownership.xml · derivative · entry 2

Bartram Richard · CIK 0001723729 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 70,000

Underlying: Common Stock · 70,000 shares

Expires 2036-02-02

F2 · derivative.exercise_date: The shares underlying this option vest and become exercisable in forty eight (48) equal monthly installments, beginning on March 2, 2026, subject to the Reporting Person's continued service on such vesting date.

SEC source: 0001193125-26-035584 · ownership.xml · nonDerivative · entry 1

Bartram Richard · CIK 0001723729 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 15,000

F1 · shares: Represents the grant of restricted stock units (RSUs). The RSUs will vest over a four (4) year period in equal quarterly installments, subject to the Reporting Person's continued service on such vesting date.

SEC source: 0001193125-26-018702 · ownership.xml · derivative · entry 1

Stelzer Laurie · CIK 0001644348 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 32,000

Underlying: Common Stock · 32,000 shares

Expires 2036-01-20

F1 · derivative.exercise_date: One-third of the shares underlying this option will vest and become exercisable on January 20, 2027, the anniversary of the date of grant, with the remainder vesting monthly over the subsequent two year period, subject to the Reporting Person's continued service on each such vesting date.

SEC source: 0001193125-25-294675 · ownership.xml · derivative · entry 1

Hoerter Steven L. · CIK 0001533451 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 8,000

Underlying: Common Stock · 8,000 shares

Expires 2035-11-21

F1 · derivative.exercise_date: The grant will vest in equal monthly installments over a one-year period from November 6, 2025, subject to the non-employee director's continued services to the Company.

SEC source: 0001193125-26-168530 · ownership.xml · derivative · entry 1

Hoerter Steven L. · CIK 0001533451 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 0 shares

Expires 2035-11-21

F1 · shares: Pursuant to the Company's Non-Employee Director Compensation Policy, these grants were adjusted downward such that the non-employee Director's annual equity compensation in 2025 totals no more than $1,000,000 based on the aggregate grant date fair value as determined in accordance with FASB Topic ASC 718.

F2 · derivative.exercise_date: The grant will vest in equal monthly installments over a one-year period from November 6, 2025, subject to the non-employee director's continued services to the Company.

F1 · derivative.underlying_shares: Pursuant to the Company's Non-Employee Director Compensation Policy, these grants were adjusted downward such that the non-employee Director's annual equity compensation in 2025 totals no more than $1,000,000 based on the aggregate grant date fair value as determined in accordance with FASB Topic ASC 718.

F1 · balance_after: Pursuant to the Company's Non-Employee Director Compensation Policy, these grants were adjusted downward such that the non-employee Director's annual equity compensation in 2025 totals no more than $1,000,000 based on the aggregate grant date fair value as determined in accordance with FASB Topic ASC 718.

SEC source: 0001193125-25-271118 · ownership.xml · derivative · entry 1

Hoerter Steven L. · CIK 0001533451 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 100,000

Underlying: Common Stock · 100,000 shares

Expires 2035-11-05

F1 · derivative.exercise_date: The grant will vest in equal monthly installments over a one-year period from the date of grant, subject to the non-employee director's continued services to the Company.

SEC source: 0001193125-26-168524 · ownership.xml · derivative · entry 1

Hoerter Steven L. · CIK 0001533451 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 33,751

Underlying: Common Stock · 33,751 shares

Expires 2035-11-05

F1 · shares: Pursuant to the Company's Non-Employee Director Compensation Policy, these grants were adjusted downward such that the non-employee Director's annual equity compensation in 2025 totals no more than $1,000,000 based on the aggregate grant date fair value as determined in accordance with FASB Topic ASC 718.

F2 · derivative.exercise_date: The grant will vest in equal monthly installments over a one-year period from the date of grant, subject to the non-employee director's continued services to the Company.

SEC source: 0001193125-25-252404 · ownership.xml · derivative · entry 3

Hawryluk P. Kent · CIK 0001673991 · Director · President & CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 129,708

Underlying: Common Stock · 182,859 shares

Expires 2032-11-06

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_date: 1/48th of the shares underlying this option vest in substantially equal monthly installments on each monthly anniversary of November 7, 2022, subject to the Reporting Person's continued service on each such vesting date, until the option vests in full on November 7, 2026. The shares underlying this option became exercisable in full on November 7, 2022, pursuant to an early-exercise provision, subject to an Issuer right of repurchase.

SEC source: 0001193125-25-252404 · ownership.xml · nonDerivative · entry 1

Hawryluk P. Kent · CIK 0001673991 · Director · President & CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 664,256

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001193125-25-245411 · ownership.xml · nonDerivative · entry 2

Hawryluk P. Kent · CIK 0001673991 · Director · President & CEO

10b5-1 filing: No plan indicated

Ownership: Indirect · By Trust

Disclosed balance after: 468,277

F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $13.60 to $13.6399, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

F2 · ownership.nature: Shares held by the P. Kent Hawryluk Revocable Trust dated January 25, 2011, of which the Reporting Person serves as trustee. The Reporting Person disclaims beneficial ownership except to the extent of any pecuniary interest therein, and this report shall not be deemed an admission that such shares are beneficially owned by him for Section 16 or any other purpose.

SEC source: 0001193125-25-243653 · ownership.xml · nonDerivative · entry 1

Hoerter Steven L. · CIK 0001533451 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · By Trust

Disclosed balance after: 20,000

F1 · ownership.nature: Shares held by the Steven L Hoerter Revocable Trust dated November 2, 2018, of which the Reporting Person serves as trustee. The Reporting Person disclaims beneficial ownership except to the extent of any pecuniary interest therein, and this report shall not be deemed an admission that such shares are beneficially owned by him for Section 16 or any other purpose.

SEC source: 0001231919-25-000267 · form4-09302025_080948.xml · nonDerivative · entry 1

Heron Patrick J · CIK 0001365617 · Director · 10% owner

FHMLS X, L.P. · CIK 0001790880 · 10% owner

FHMLS X, L.L.C. · CIK 0001790811 · 10% owner

Topper James N · CIK 0001341382 · 10% owner

Frazier Life Sciences X, L.P. · CIK 0001790879 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · By Frazier Life Sciences X, L.P.

Disclosed balance after: 5,219,440

F1 · ownership.nature: The shares reported herein are held of record by Frazier Life Sciences X, L.P. FHMLS X, L.P. is the general partner of Frazier Life Sciences X, L.P. and FHMLS X, L.L.C. is the general partner of FHMLS X, L.P. James N. Topper and Patrick J. Heron are the sole managing members of FHMLS X, L.L.C. and share voting and investment power over the shares held by Frazier Life Sciences X, L.P. Dr. Topper and Mr. Heron disclaim beneficial ownership of such securities except to the extent of their pecuniary interest therein.

SEC source: 0000950170-25-082773 · ownership.xml · derivative · entry 1

Mathers Edward T · CIK 0001328625 · Director · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 16,000

Underlying: Common Stock · 16,000 shares

Expires 2035-06-05

F1 · derivative.exercise_date: The grant will vest in full on the earlier of the one-year anniversary of the grant date or on the date of our next annual meeting of stockholders, subject to the non-employee director's continued services to the Company.

SEC source: 0000950170-25-082713 · ownership.xml · derivative · entry 1

Hoerter Steven L. · CIK 0001533451 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 16,000

Underlying: Common Stock · 16,000 shares

Expires 2035-06-05

F1 · derivative.exercise_date: The grant will vest in full on the earlier of the one-year anniversary of the grant date or on the date of our next annual meeting of stockholders, subject to the non-employee director's continued services to the Company.

SEC source: 0000950170-25-082703 · ownership.xml · derivative · entry 1

Aynechi Tiba · CIK 0001669220 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 16,000

Underlying: Common Stock · 16,000 shares

Expires 2035-06-05

F1 · derivative.exercise_date: The grant will vest in full on the earlier of the one-year anniversary of the grant date or on the date of our next annual meeting of stockholders, subject to the non-employee director's continued services to the Company.

SEC source: 0000950170-25-082702 · ownership.xml · derivative · entry 1

CORNELIUS JAMES M · CIK 0001198959 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 16,000

Underlying: Common Stock · 16,000 shares

Expires 2035-06-05

F1 · derivative.exercise_date: The grant will vest in full on the earlier of the one-year anniversary of the grant date or on the date of our next annual meeting of stockholders, subject to the non-employee director's continued services to the Company.

SEC source: 0000950170-25-082701 · ownership.xml · derivative · entry 1

Ryder Steven · CIK 0001872868 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 16,000

Underlying: Common Stock · 16,000 shares

Expires 2035-06-05

F1 · derivative.exercise_date: The grant will vest in full on the earlier of the one-year anniversary of the grant date or on the date of our next annual meeting of stockholders, subject to the non-employee director's continued services to the Company.

SEC source: 0000950170-25-082699 · ownership.xml · derivative · entry 1

Heron Patrick J · CIK 0001365617 · Director · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 16,000

Underlying: Common Stock · 16,000 shares

Expires 2035-06-05

F1 · derivative.exercise_date: The grant will vest in full on the earlier of the one-year anniversary of the grant date or on the date of our next annual meeting of stockholders, subject to the non-employee director's continued services to the Company.

SEC source: 0000950170-25-082698 · ownership.xml · derivative · entry 1

Pescovitz Ora H. · CIK 0001519624 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 16,000

Underlying: Common Stock · 16,000 shares

Expires 2035-06-05

F1 · derivative.exercise_date: The grant will vest in full on the earlier of the one-year anniversary of the grant date or on the date of our next annual meeting of stockholders, subject to the non-employee director's continued services to the Company.

SEC source: 0000950170-25-052685 · ownership.xml · nonDerivative · entry 1

Pescovitz Ora H. · CIK 0001519624 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 24,329

F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $5.65 to $6.30, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

SEC source: 0000950170-25-052313 · ownership.xml · derivative · entry 1

Hoerter Steven L. · CIK 0001533451 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 32,000

Underlying: Common Stock · 32,000 shares

Expires 2035-04-07

F1 · derivative.exercise_date: One-third of the shares underlying this option will vest and become exercisable on April 7, 2026, the anniversary of the date of grant, with the remainder vesting monthly over the subsequent two year period, subject to the Reporting Person's continued service on each such vesting date.